A new era in the management of adult patients with moderate to severe Prurigo Nodularis
Recorded webinar
A new era in the management of adult patients with moderate to severe Prurigo Nodularis
In this presentation, Assoc. Prof. Shawn Kwatra discusses the management of prurigo nodularis (PN) in a new treatment era with Dupixent (dupilumab) as an approved biologic therapy in the European Union. He also covers dupilumab's clinical trials and shares early treatment experiences in patients with moderate to severe PN*.
.jpg/jcr:content/jcr_content%20(1).jpg)
Speaker: Shawn Kwatra
Associate Professor of Dermatology @Johns Hopkins University School of Medicine, Baltimore, USA
Dr. Shawn Kwatra, MD is an Associate Professor of Dermatology at the Johns Hopkins University School of Medicine in Baltimore, MD, USA and Director of the Johns Hopkins Itch Center. His areas of clinical expertise include chronic pruritus, prurigo nodularis, atopic dermatitis, and dermatology for ethnic skin. Dr. Kwatra is funded by the National Institutes of Health, Dermatology Foundation, Skin of Color Society, Society for Investigative Dermatology and industry partners. Dr. Kwatra has been an author or co-author on over 200 publications in peer-reviewed international journals and is a member of the Board of Directors of the Skin of Color Society.
Vill du läsa mer om behandling med Dupixent®(dupilumab) för de olika indikationerna, klicka in på Fass.se
